|
|
Article: Phase II Patient's Blood Clot Halts IDEC Antibody Trials.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
IDEC Pharmaceuticals Corp.'s stock dipped Tuesday on news that the company voluntarily stopped clinical trials of its anti-CD40 ligand monoclonal antibody, IDEC-131, after one patient developed a blood clot in the lower leg.
The company's stock (NASDAQ:IDPH) closed Tuesday at $32.03, down $6.34, or 16.52 percent.
Also, it is likely that the trading price was affected by IDEC's disclosure that Medicare will not commence reimbursement of Zevalin until Oct. 1, a three-month delay. In February, the FDA approved Zevalin for use in non-Hodgkin's lymphoma patients. (See BioWorld Today, Feb. 21, 2002.)
But the more pressing ...